Literature DB >> 25662333

Crucial role for the VWF A1 domain in binding to type IV collagen.

Veronica H Flood1, Abraham C Schlauderaff2, Sandra L Haberichter2, Tricia L Slobodianuk3, Paula M Jacobi3, Daniel B Bellissimo3, Pamela A Christopherson3, Kenneth D Friedman3, Joan Cox Gill2, Raymond G Hoffmann4, Robert R Montgomery2.   

Abstract

Von Willebrand factor (VWF) contains binding sites for platelets and for vascular collagens to facilitate clot formation at sites of injury. Although previous work has shown that VWF can bind type IV collagen (collagen 4), little characterization of this interaction has been performed. We examined the binding of VWF to collagen 4 in vitro and extended this characterization to a murine model of defective VWF-collagen 4 interactions. The interactions of VWF and collagen 4 were further studied using plasma samples from a large study of both healthy controls and subjects with different types of von Willebrand disease (VWD). Our results show that collagen 4 appears to bind VWF exclusively via the VWF A1 domain, and that specific sequence variations identified through VWF patient samples and through site-directed mutagenesis in the VWF A1 domain can decrease or abrogate this interaction. In addition, VWF-dependent platelet binding to collagen 4 under flow conditions requires an intact VWF A1 domain. We observed that decreased binding to collagen 4 was associated with select VWF A1 domain sequence variations in type 1 and type 2M VWD. This suggests an additional mechanism through which VWF variants may alter hemostasis.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25662333      PMCID: PMC4383803          DOI: 10.1182/blood-2014-11-610824

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.

Authors:  Daniel B Bellissimo; Pamela A Christopherson; Veronica H Flood; Joan Cox Gill; Kenneth D Friedman; Sandra L Haberichter; Amy D Shapiro; Thomas C Abshire; Cindy Leissinger; W Keith Hoots; Jeanne M Lusher; Margaret V Ragni; Robert R Montgomery
Journal:  Blood       Date:  2011-12-23       Impact factor: 22.113

2.  Critical von Willebrand factor A1 domain residues influence type VI collagen binding.

Authors:  V H Flood; J C Gill; P A Christopherson; D B Bellissimo; K D Friedman; S L Haberichter; S R Lentz; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

3.  A family with type 2M VWD with normal VWF:RCo but reduced VWF:CB and a M1761K mutation in the A3 domain.

Authors:  D Keeling; J Beavis; R Marr; K Sukhu; P Bignell
Journal:  Haemophilia       Date:  2011-10-17       Impact factor: 4.287

4.  The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.

Authors:  Sonia Philipose; Viktoria Konya; Ivana Sreckovic; Gunther Marsche; Irmgard T Lippe; Bernhard A Peskar; Akos Heinemann; Rufina Schuligoi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

5.  Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD.

Authors:  V H Flood; C A Lederman; J S Wren; P A Christopherson; K D Friedman; R G Hoffmann; R R Montgomery
Journal:  J Thromb Haemost       Date:  2010-03-23       Impact factor: 5.824

6.  ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.

Authors:  F Rodeghiero; A Tosetto; T Abshire; D M Arnold; B Coller; P James; C Neunert; D Lillicrap
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

7.  Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.

Authors:  C M Pruss; M Golder; A Bryant; C Hegadorn; S Haberichter; D Lillicrap
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

8.  COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke.

Authors:  Marion Jeanne; Cassandre Labelle-Dumais; Jeff Jorgensen; W Berkeley Kauffman; Grazia M Mancini; Jack Favor; Valerie Valant; Steven M Greenberg; Jonathan Rosand; Douglas B Gould
Journal:  Am J Hum Genet       Date:  2011-12-29       Impact factor: 11.025

9.  COL4A1 mutations in patients with sporadic late-onset intracerebral hemorrhage.

Authors:  Yi-Chinn Weng; Akshata Sonni; Cassandre Labelle-Dumais; Michelle de Leau; W Berkeley Kauffman; Marion Jeanne; Alessandro Biffi; Steven M Greenberg; Jonathan Rosand; Douglas B Gould
Journal:  Ann Neurol       Date:  2012-04       Impact factor: 10.422

10.  Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients.

Authors:  G Castaman; A B Federici; A Tosetto; S La Marca; F Stufano; P M Mannucci; F Rodeghiero
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

View more
  30 in total

1.  Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Authors:  Veronica H Flood; Pamela A Christopherson; Joan Cox Gill; Kenneth D Friedman; Sandra L Haberichter; Daniel B Bellissimo; Rupa A Udani; Mahua Dasgupta; Raymond G Hoffmann; Margaret V Ragni; Amy D Shapiro; Jeanne M Lusher; Steven R Lentz; Thomas C Abshire; Cindy Leissinger; W Keith Hoots; Marilyn J Manco-Johnson; Ralph A Gruppo; Lisa N Boggio; Kate T Montgomery; Anne C Goodeve; Paula D James; David Lillicrap; Ian R Peake; Robert R Montgomery
Journal:  Blood       Date:  2016-02-09       Impact factor: 22.113

2.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

Review 3.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

4.  Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Authors:  Brian Cooley; William Funkhouser; Dougald Monroe; Ashley Ezzell; David M Mann; Feng-Chang Lin; Paul E Monahan; Darrel W Stafford
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

5.  Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.

Authors:  T L Slobodianuk; C Kochelek; J Foeckler; S Kalloway; H Weiler; V H Flood
Journal:  J Thromb Haemost       Date:  2018-12-18       Impact factor: 5.824

6.  New advances in the diagnosis of von Willebrand disease.

Authors:  Ruchika Sharma; Sandra L Haberichter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

7.  von Willebrand factor binding to myosin assists in coagulation.

Authors:  Veronica H Flood; Tricia L Slobodianuk; Daniel Keesler; Hannah K Lohmeier; Scot Fahs; Liyun Zhang; Pippa Simpson; Robert R Montgomery
Journal:  Blood Adv       Date:  2020-01-14

8.  The Von Willebrand Factor A1-Collagen III Interaction Is Independent of Conformation and Type 2 Von Willebrand Disease Phenotype.

Authors:  Venkata R Machha; Alexander Tischer; Laurie Moon-Tasson; Matthew Auton
Journal:  J Mol Biol       Date:  2016-11-24       Impact factor: 5.469

Review 9.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 10.  Application of microfluidic devices in studies of thrombosis and hemostasis.

Authors:  Changjie Zhang; Sriram Neelamegham
Journal:  Platelets       Date:  2017-06-05       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.